The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study

Martin Huth Ruwald; Morten Lock Hansen; Morten Lamberts; Carolina Malta Hansen; Michael Vinther Højgaard; Lars Køber; Christian Torp-Pedersen; Jim Hansen; Gunnar Hilmar Gislason

doi:10.1093/europace/eus154

The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study

Martin Huth Ruwald, Morten Lock Hansen, Morten Lamberts, Carolina Malta Hansen, Michael Vinther Højgaard, Lars Køber, Christian Torp-Pedersen, Jim Hansen, Gunnar Hilmar Gislason

64 Citationer (Scopus)

Abstract

AimsSyncope is a common cause for hospitalization and may be related to comorbidity and concurrent medication. The objective of this study was to determine the incidence, comorbidity, and pharmacotherapy in a nationwide cohort of patients hospitalized with syncope.Methods and resultsAn observational study including patients with the diagnosis of syncope identified from the Danish National Patient Register in the period 19972009. All patients were matched on sex and age with five controls from the Danish population. We estimated the incidence of syncope and the association with comorbidities and pharmacotherapy by conditional logistic regression analyses. We identified 127 508 patients with a first-time diagnosis of syncope [median age 65 years (interquartile range 4981), 52.6 female]. The age distribution of the patients showed three peaks around 20, 60, and 80 years of age with the third peak occurring 57 years earlier in males. Cardiovascular disease and cardiovascular drug therapy was present in 28 and 48 of the patients, respectively. We found significant association between cardiovascular disease and the risk of admission for syncope increasing with younger age; age 029 years [odds ratio (OR) 5.8, confidence interval (CI): 5.26.4), age 3049 (OR 4.4, CI: 4.24.6), age 5079 (OR 2.9, CI: 2.83.0), and age above 80 (OR 2.0, CI: 1.92.0). Cardiovascular pharmacotherapy associated with age and risk of syncope was similar.ConclusionIn a nationwide cohort of patients hospitalized for first syncope we found significant association between cardiovascular comorbidity and pharmacotherapy and the risk of syncope. The occurrence of syncope displayed an age distribution with important gender-specific differences and higher incidence rates than previously reported.

Originalsprog	Engelsk
Tidsskrift	Europace
Vol/bind	14
Udgave nummer	10
Sider (fra-til)	1506-14
Antal sider	9
ISSN	1099-5129
DOI	https://doi.org/10.1093/europace/eus154
Status	Udgivet - okt. 2012

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1093/europace/eus154

eus154.pdfForlagets udgivne version, 250 KB

https://academic.oup.com/europace/article-pdf/14/10/1506/7277513/eus154.pdf

Citationsformater

@article{4e5849079ce24e3590ea5df2e677f93e,

title = "The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study",

abstract = "AimsSyncope is a common cause for hospitalization and may be related to comorbidity and concurrent medication. The objective of this study was to determine the incidence, comorbidity, and pharmacotherapy in a nationwide cohort of patients hospitalized with syncope.Methods and resultsAn observational study including patients with the diagnosis of syncope identified from the Danish National Patient Register in the period 19972009. All patients were matched on sex and age with five controls from the Danish population. We estimated the incidence of syncope and the association with comorbidities and pharmacotherapy by conditional logistic regression analyses. We identified 127 508 patients with a first-time diagnosis of syncope [median age 65 years (interquartile range 4981), 52.6 female]. The age distribution of the patients showed three peaks around 20, 60, and 80 years of age with the third peak occurring 57 years earlier in males. Cardiovascular disease and cardiovascular drug therapy was present in 28 and 48 of the patients, respectively. We found significant association between cardiovascular disease and the risk of admission for syncope increasing with younger age; age 029 years [odds ratio (OR) 5.8, confidence interval (CI): 5.26.4), age 3049 (OR 4.4, CI: 4.24.6), age 5079 (OR 2.9, CI: 2.83.0), and age above 80 (OR 2.0, CI: 1.92.0). Cardiovascular pharmacotherapy associated with age and risk of syncope was similar.ConclusionIn a nationwide cohort of patients hospitalized for first syncope we found significant association between cardiovascular comorbidity and pharmacotherapy and the risk of syncope. The occurrence of syncope displayed an age distribution with important gender-specific differences and higher incidence rates than previously reported.",

author = "Ruwald, {Martin Huth} and Hansen, {Morten Lock} and Morten Lamberts and Hansen, {Carolina Malta} and H{\o}jgaard, {Michael Vinther} and Lars K{\o}ber and Christian Torp-Pedersen and Jim Hansen and Gislason, {Gunnar Hilmar}",

year = "2012",

month = oct,

doi = "10.1093/europace/eus154",

language = "English",

volume = "14",

pages = "1506--14",

journal = "Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope

T2 - a Danish nationwide study

AU - Ruwald, Martin Huth

AU - Hansen, Morten Lock

AU - Lamberts, Morten

AU - Hansen, Carolina Malta

AU - Højgaard, Michael Vinther

AU - Køber, Lars

AU - Torp-Pedersen, Christian

AU - Hansen, Jim

AU - Gislason, Gunnar Hilmar

PY - 2012/10

Y1 - 2012/10

N2 - AimsSyncope is a common cause for hospitalization and may be related to comorbidity and concurrent medication. The objective of this study was to determine the incidence, comorbidity, and pharmacotherapy in a nationwide cohort of patients hospitalized with syncope.Methods and resultsAn observational study including patients with the diagnosis of syncope identified from the Danish National Patient Register in the period 19972009. All patients were matched on sex and age with five controls from the Danish population. We estimated the incidence of syncope and the association with comorbidities and pharmacotherapy by conditional logistic regression analyses. We identified 127 508 patients with a first-time diagnosis of syncope [median age 65 years (interquartile range 4981), 52.6 female]. The age distribution of the patients showed three peaks around 20, 60, and 80 years of age with the third peak occurring 57 years earlier in males. Cardiovascular disease and cardiovascular drug therapy was present in 28 and 48 of the patients, respectively. We found significant association between cardiovascular disease and the risk of admission for syncope increasing with younger age; age 029 years [odds ratio (OR) 5.8, confidence interval (CI): 5.26.4), age 3049 (OR 4.4, CI: 4.24.6), age 5079 (OR 2.9, CI: 2.83.0), and age above 80 (OR 2.0, CI: 1.92.0). Cardiovascular pharmacotherapy associated with age and risk of syncope was similar.ConclusionIn a nationwide cohort of patients hospitalized for first syncope we found significant association between cardiovascular comorbidity and pharmacotherapy and the risk of syncope. The occurrence of syncope displayed an age distribution with important gender-specific differences and higher incidence rates than previously reported.

AB - AimsSyncope is a common cause for hospitalization and may be related to comorbidity and concurrent medication. The objective of this study was to determine the incidence, comorbidity, and pharmacotherapy in a nationwide cohort of patients hospitalized with syncope.Methods and resultsAn observational study including patients with the diagnosis of syncope identified from the Danish National Patient Register in the period 19972009. All patients were matched on sex and age with five controls from the Danish population. We estimated the incidence of syncope and the association with comorbidities and pharmacotherapy by conditional logistic regression analyses. We identified 127 508 patients with a first-time diagnosis of syncope [median age 65 years (interquartile range 4981), 52.6 female]. The age distribution of the patients showed three peaks around 20, 60, and 80 years of age with the third peak occurring 57 years earlier in males. Cardiovascular disease and cardiovascular drug therapy was present in 28 and 48 of the patients, respectively. We found significant association between cardiovascular disease and the risk of admission for syncope increasing with younger age; age 029 years [odds ratio (OR) 5.8, confidence interval (CI): 5.26.4), age 3049 (OR 4.4, CI: 4.24.6), age 5079 (OR 2.9, CI: 2.83.0), and age above 80 (OR 2.0, CI: 1.92.0). Cardiovascular pharmacotherapy associated with age and risk of syncope was similar.ConclusionIn a nationwide cohort of patients hospitalized for first syncope we found significant association between cardiovascular comorbidity and pharmacotherapy and the risk of syncope. The occurrence of syncope displayed an age distribution with important gender-specific differences and higher incidence rates than previously reported.

U2 - 10.1093/europace/eus154

DO - 10.1093/europace/eus154

M3 - Journal article

C2 - 22588456

SN - 1099-5129

VL - 14

SP - 1506

EP - 1514

JO - Europace

JF - Europace

IS - 10

ER -

The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater